PUBLISHER: TechNavio | PRODUCT CODE: 1184130
PUBLISHER: TechNavio | PRODUCT CODE: 1184130
Technavio has been monitoring the human combination vaccines market and is forecast to grow by $6046.98 mn during 2022-2027, accelerating at a CAGR of 8.13% during the forecast period. Our report on the human combination vaccines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing antiviral drug resistance, increase in pediatric population, and rise in cases of infectious diseases.
Technavio's human combination vaccines market is segmented as below:
By Type
By Channel
By Geographical Landscape
This study identifies the threat from bioterrorism as one of the prime reasons driving the human combination vaccines market growth during the next few years. Also, growing interest in research and development of new vaccines and presence of government-sponsored programs will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the human combination vaccines market covers the following areas:
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human combination vaccines market vendors that include Abbott Laboratories, Arabio, Bharat Biotech Ltd., Biological E. Ltd., Cadila Healthcare Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Grifols SA, LG Corp., Meiji Holdings Co. Ltd., Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Panacea Biotec Ltd., Pfizer Inc., PT Bio Farma, Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Walvax Biotechnology Co. Ltd. Also, the human combination vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: